Homology Medicines Inc reports results for the quarter ended in June - Earnings Summary

Q32 Bio

14/08/2023 22:24

* Homology Medicines Inc  FIXX.OQ  reported a quarterly
adjusted
loss of 61 cents​​ per share for the quarter ended in June. The
mean expectation of three analysts for the quarter was for a
loss of 47 cents per share.
    * Revenue fell 55.9% to $354.00 thousand from a year ago;
analysts
expected $841.33 thousand. 
    * Homology Medicines Inc's reported EPS for the quarter was
a loss
of 61 cents​.
    * The mean earnings estimate of analysts had fallen by
about 6.3%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Homology Medicines Inc shares had risen by 32.2% this
quarter and lost 7.1% so far this year.
    * The company reported a quarterly loss of $35.04 million.
    * Wall Street's median 12-month price target for Homology
Medicines Inc is $2.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 14 at 09:24 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.47          -0.61          Missed
 Mar. 31 2023      -0.53          -0.50          Beat
 Dec. 31 2022      -0.50          -0.60          Missed
 Sep. 30 2022      -0.47          -0.59          Missed